Detalhe da pesquisa
1.
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Blood
; 133(6): 540-549, 2019 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510079
2.
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
Blood
; 133(6): 530-539, 2019 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510080
3.
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
Haematologica
; 106(1): 230-237, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31949012
4.
Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.
Blood Adv
; 2(17): 2176-2185, 2018 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30171081